{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:09:57Z","timestamp":1780571397883,"version":"3.54.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Institute for Health Research (NIHR) Academic Clinical Fellowship"},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIHR Royal Marsden\/Institute of Cancer Research (ICR) Biomedical Research Centre"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>BRAFV600E-mutant metastatic colorectal cancer (mCRC) is an aggressive molecular subtype associated with poor prognosis and relative chemoresistance. Outcomes following progression on chemotherapy and MAPK-targeted therapy with encorafenib plus cetuximab remain poor, highlighting an unmet need for effective later-line treatments. Immune checkpoint inhibitors have limited activity in microsatellite-stable (MSS) mCRC, and predictive biomarkers beyond mismatch repair deficiency remain poorly defined. We report a patient with BRAFV600E-mutant MSS mCRC who achieved a prolonged response to PD-1 blockade with pembrolizumab following a dynamic increase in tumor mutational burden (TMB). A 58-year-old woman initially responded to first-line chemotherapy but subsequently progressed on multiple treatment lines, including encorafenib plus cetuximab. Longitudinal genomic profiling using tumor tissue and circulating tumor DNA (ctDNA) revealed persistent BRAFV600E signaling with molecular evolution, including acquisition of a PIK3R1 variant associated with resistance to MAPK inhibition and emergence of TMB-high status. Fifth-line pembrolizumab produced a dramatic radiological response, with ongoing disease control more than 2 years later. We discuss the mechanistic framework by which a subset of BRAFV600E-mutant MSS mCRC may respond to immune checkpoint inhibition through an inflamed immune microenvironment driven by constitutive MAPK signaling. This case illustrates the interplay between tumor-agnostic biomarkers such as TMB-high and tumor-specific context, and highlights the value of longitudinal genomic profiling, including ctDNA, to identify resistance mechanisms and guide treatment selection.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag161","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T12:20:21Z","timestamp":1777638021000},"source":"Crossref","is-referenced-by-count":0,"title":["Prolonged response to pembrolizumab in BRAFV600E microsatellite stable metastatic colorectal cancer following an increase in tumor mutational burden"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4224-1307","authenticated-orcid":false,"given":"Yu-Hsuen","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Gastrointestinal Unit, The Royal Marsden Hospital , London, SW3 6JJ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1496-6792","authenticated-orcid":false,"given":"Naureen","family":"Starling","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gastrointestinal Unit, The Royal Marsden Hospital , London, SW3 6JJ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cartwright","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Gastrointestinal Unit, The Royal Marsden Hospital , London, SW3 6JJ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2026060406354109700_oyag161-B1","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.clcc.2024.04.004","article-title":"BRAFV600E-mutant metastatic colorectal cancer: current evidence, future directions, and research priorities","volume":"23","author":"Piercey","year":"2024","journal-title":"Clin Colorectal Cancer"},{"key":"2026060406354109700_oyag161-B2","doi-asserted-by":"publisher","first-page":"100603","DOI":"10.1016\/j.esmoop.2022.100603","article-title":"Real-world first-line treatment of patients with BRAFV600E-mutant metastatic colorectal cancer: the CAPSTAN CRC study","volume":"7","author":"Martinelli","year":"2022","journal-title":"ESMO Open"},{"key":"2026060406354109700_oyag161-B3","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026060406354109700_oyag161-B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2026.44.2_suppl.13","article-title":"BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mcrc)","volume":"44","author":"Kopetz","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026060406354109700_oyag161-B5","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2501912","article-title":"Encorafenib, cetuximab, and mFOLFOX6 in BRAF-mutated colorectal cancer","volume":"392","author":"Elez","year":"2025","journal-title":"N Engl J Med"},{"key":"2026060406354109700_oyag161-B6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E\u2013mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026060406354109700_oyag161-B7","doi-asserted-by":"publisher","first-page":"102996","DOI":"10.1016\/j.esmoop.2024.102996","article-title":"Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset","volume":"9","author":"Germani","year":"2024","journal-title":"ESMO Open"},{"key":"2026060406354109700_oyag161-B8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"2026060406354109700_oyag161-B9","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/s41591-024-03235-9","article-title":"Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial","volume":"30","author":"Kopetz","year":"2024","journal-title":"Nat Med"},{"key":"2026060406354109700_oyag161-B10","doi-asserted-by":"publisher","first-page":"S478","DOI":"10.1016\/j.annonc.2025.08.1304","article-title":"729MO circulating tumour (ct) DNA analysis of BRAF V600E dynamics and changes in genomic landscape in patients (pts) with first-line (1L) BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated in BREAKWATER","volume":"36","author":"Kopetz","year":"2025","journal-title":"Ann Oncol."},{"key":"2026060406354109700_oyag161-B11","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41416-020-01147-2","article-title":"Mutational profiles associated with resistance in patients with BRAFV600E mutant colorectal cancer treated with cetuximab and encorafenib +\/\u2212 binimetinib or alpelisib","volume":"124","author":"Huijberts","year":"2021","journal-title":"Br J Cancer"},{"key":"2026060406354109700_oyag161-B12","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/ng1834","article-title":"CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer","volume":"38","author":"Weisenberger","year":"2006","journal-title":"Nat Genet"},{"key":"2026060406354109700_oyag161-B13","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"2026060406354109700_oyag161-B14","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/modpathol.2016.95","article-title":"PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes","volume":"29","author":"Rosenbaum","year":"2016","journal-title":"Mod Pathol"},{"key":"2026060406354109700_oyag161-B15","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/j.ccell.2025.08.002","article-title":"Phase 1\/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer","volume":"43","author":"Morris","year":"2025","journal-title":"Cancer Cell"},{"key":"2026060406354109700_oyag161-B16","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s41591-022-02181-8","article-title":"Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial","volume":"29","author":"Tian","year":"2023","journal-title":"Nat Med"},{"key":"2026060406354109700_oyag161-B17","author":"National Cancer Institute (NCI)","year":"2025"},{"key":"2026060406354109700_oyag161-B18","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1158\/1078-0432.CCR-20-2404","article-title":"ARID1A mutation may define an immunologically active subgroup in patients with microsatellite stable colorectal cancer","volume":"27","author":"Mehrvarz Sarshekeh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026060406354109700_oyag161-B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: Results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026060406354109700_oyag161-B20","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(25)00239-6","article-title":"Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026060406354109700_oyag161-B21","doi-asserted-by":"publisher","first-page":"100746","DOI":"10.1016\/j.ctarc.2023.100746","article-title":"High tumor mutation burden (TMB) in microsatellite stable (MSS) colorectal cancers: diverse molecular associations point to variable pathophysiology","volume":"36","author":"Voutsadakis","year":"2023","journal-title":"Cancer Treat Res Commun"},{"key":"2026060406354109700_oyag161-B22","doi-asserted-by":"publisher","first-page":"e008638","DOI":"10.1136\/jitc-2023-008638","article-title":"Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06)","volume":"12","author":"Kim","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026060406354109700_oyag161-B23","doi-asserted-by":"publisher","first-page":"610","DOI":"10.21037\/jgo.2018.05.06","article-title":"Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition","volume":"9","author":"Fabrizio","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"2026060406354109700_oyag161-B24","doi-asserted-by":"publisher","first-page":"104108","DOI":"10.1016\/j.esmoop.2024.104108","article-title":"Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes","volume":"10","author":"Yamaguchi","year":"2025","journal-title":"ESMO Open"},{"key":"2026060406354109700_oyag161-B25","doi-asserted-by":"publisher","first-page":"4972","DOI":"10.1038\/s41467-025-60369-1","article-title":"Tissue-agnostic cancer therapies: promise, reality, and the path forward","volume":"16","author":"Subbiah","year":"2025","journal-title":"Nat Commun"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag161\/68236930\/oyag161.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag161\/68236930\/oyag161.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/6\/oyag161\/68236930\/oyag161.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:35:48Z","timestamp":1780569348000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag161\/8671599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag161","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,5,6]]},"article-number":"oyag161"}}